Halting pancreatic cancer spread: Protein-degrading drugs show promise in preclinical models

Last year, researchers at the University of California, Riverside, developed a novel “molecular crowbar” strategy to degrade the oncogenic enzyme Pin1, a protein that is overexpressed in many tumors, including pancreatic cancer. They designed compounds that bind to Pin1 and destabilize its structure, causing its cellular degradation.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup